Navidea Biopharmaceuticals, Inc. NAVBQ
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 61.62% | -16.30% | -29.38% | -40.77% | -- |
| Total Depreciation and Amortization | 25.92% | 22.38% | 24.55% | 21.58% | -- |
| Total Amortization of Deferred Charges | 520.64% | -- | -- | -- | -- |
| Total Other Non-Cash Items | -172.70% | -173.84% | 57.42% | 125.70% | -- |
| Change in Net Operating Assets | 115.26% | 481.91% | 440.32% | 1,079.50% | -- |
| Cash from Operations | 85.98% | 16.05% | 12.05% | 7.61% | -- |
| Capital Expenditure | 58.51% | 46.28% | -150.00% | -146.35% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 42.17% | 12.01% | -7.56% | -15.28% | -- |
| Cash from Investing | 44.74% | 18.05% | -18.49% | -26.38% | -- |
| Total Debt Issued | -13.33% | -- | -- | -- | -- |
| Total Debt Repaid | -36.04% | 40.97% | -5.37% | -27.98% | -- |
| Issuance of Common Stock | 29,163.64% | -100.00% | -100.00% | -91.88% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 229.44% | 36.94% | -51.33% | -56.86% | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -7,112.33% | -1,898.03% | -1,347.14% | -1,291.04% | -- |
| Cash from Financing | 137.59% | 91.52% | -41.02% | -48.53% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 185.70% | 81.19% | -243.23% | -174.58% | -- |